Holen Sie sich die Stockscreener-App
1.17
12.03%
-0.16
Handel nachbörslich:
1.24
0.07
+5.98%
Schlusskurs vom Vortag:
$1.33
Offen:
$1.31
24-Stunden-Volumen:
121.40K
Relative Volume:
0.16
Marktkapitalisierung:
$4.71M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.10M
KGV:
-0.2205
EPS:
-5.3059
Netto-Cashflow:
$-8.30M
1W Leistung:
-4.10%
1M Leistung:
-2.50%
6M Leistung:
-46.33%
1J Leistung:
-83.14%
1-Tages-Spanne:
$1.17
$1.35
1-Wochen-Bereich:
$1.17
$1.37
52-Wochen-Spanne:
$1.10
$8.00
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Firmenname
Dermata Therapeutics Inc
Sektor
Branche
Telefon
(858)-223-0882
Adresse
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Compare DRMA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
1.17 | 4.71M | 0 | -7.10M | -8.30M | -5.3059 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dermata Therapeutics Inc Aktie (DRMA) Neueste Nachrichten
Dermata Therapeutics Inc (DRMA) Institutional Confidence - TradingKey
Dermata Therapeutics Inc (DRMA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Dermata Therapeutics Inc (DRMAW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Dermata Therapeutics Inc (DRMAW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dermata Therapeutics Inc (DRMA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Dermata Therapeutics Inc (DRMA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Dermata Therapeutics Inc (DRMAW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Dermata Therapeutics Inc (DRMA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dermata Therapeutics Inc (DRMAW) Institutional Confidence - TradingKey
Dermata Therapeutics Inc (DRMA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Dermata Therapeutics Inc (DRMA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dermata Therapeutics Inc - TradingKey
Dermata Therapeutics Inc (DRMAW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dermata Therapeutics Inc (DRMAW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Dermata Therapeutics (NASDAQ: DRMA) director reports small open-market stock sale - Stock Titan
Dermata Therapeutics Strategically Expands into Skincare with Executive Appointment - timothysykes.com
Dermata Therapeutics Warrant (DRMAW) Slides 19.73% as Price Nears Critical Floor at $0.01Dark Pool Volume - newsline.com
DRMA Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Control Amid Pipeline ProgressQuarterly Financial Update - newsline.com
DRMA Q1 2026 Earnings: Better-than-Expected Loss Reduction Amidst Pipeline Development FocusShare Dilution Risk - newsline.com
DRMA Q1 2026 Earnings: Narrower Loss Surpasses Expectations as Clinical Advances ContinueSlow Growth Warning - newsline.com
Dermata Therapeutics (DRMA) Edges Higher as Stock Tests Key Resistance LevelsBlue Chip Entry Points - newsline.com
Lixte Biotechnology Holdings, Inc. (LIXTW) Stock Price, News, Quote & History - Yahoo! Finance Canada
DRMA Q1 2026 Earnings: Positive EPS Surprise as Dermata Advances PipelinePreliminary Results - newsline.com
CFO Kyri Van Hoose (DRMA) discloses 9% Dermata ownership in Schedule 13D - Stock Titan
[EFFECT] Dermata Therapeutics, Inc. SEC Filing - Stock Titan
Dermata Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
Dermata Therapeutics Warrant (DRMAW) Holds at Penny Level – Key Levels to WatchAI Trade Signals - newsline.com
Dermata Therapeutics (NASDAQ: DRMA) files $100M shelf registration - Stock Titan
Dermata Therapeutics (DRMA) Stages Modest Recovery – Support Holds Above $1.28Keltner Channel - The Legal Advocate
Dermata Therapeutics (DRMA) Shares Climb 3.85% as Stock Tests Key Resistance LevelsVolume Breakout Ideas - The Legal Advocate
Dermata Therapeutics Adopts Fourth Amendment to 2021 Omnibus Equity Incentive Plan – Form 8-K Filing Summary - Minichart
Dermata Therapeutics Shareholders Approve Equity Plan and Directors - TipRanks
Dermata (NASDAQ: DRMA) investors approve equity plan expansion and warrant changes - Stock Titan
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
DRMA Q1 2026 Earnings: Narrower Loss Than Expected Bolsters Investor SentimentRevenue Report - Newser
Dermata Therapeutics (NASDAQ: DRMA) files $100M shelf for stock, warrants - Stock Titan
DRMA Q1 2026 Earnings: Narrower-than-Expected Loss Marks Progress for Clinical-Stage BiotechEarnings Yield Spread - The Legal Advocate
Dermata Therapeutics (DRMA) Slides 0.8% as Shares Hover Near Support at $1.18Virgin POC - Newser
Dermata Therapeutics Warrant (DRMAW) Holds at $0.01 as Trading Remains FlatGap Fill Strategy - Newser
Dermata shares rise after USPTO issues patent notice of allowance - MSN
Dermata Therapeutics, Inc.Common Stock (NQ: DRMA - FinancialContent
DRMA Should I Buy - Intellectia AI
Inhibikase Therapeutics, Inc.Common Stock (NQ: IKT - FinancialContent
DRMA Stock Chart | DERMATA THERAPEUTICS INC (NASDAQ:DRMA) - ChartMill
DRMA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Dermata Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Dermata Therapeutics (NASDAQ:DRMA) Q1 2026 Earnings: Narrowing Losses and Strategic Pivot to DTC Skincare - ChartMill
Intracoastal-linked holders report 4.99% stake in Dermata (NASDAQ: DRMA) - Stock Titan
Once-weekly Tome mask aims to bring professional skincare home by mid-2026 - Stock Titan
[10-Q] Dermata Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Dermata Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Finanzdaten der Dermata Therapeutics Inc-Aktie (DRMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):